Drug intelligence / Profile preview

diphtheria and tetanus toxoids vaccine

Development stage
Unknown
Lead developer
Wuhan Institute of Biological Products
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

The Chinese DT vaccine refers to the locally manufactured diphtheria and tetanus toxoids vaccine (adsorbed) used in the People's Republic of China. It is a combination vaccine containing purified diphtheria toxoid and tetanus toxoid adsorbed onto an aluminum-based adjuvant, typically aluminum hydroxide. This vaccine is primarily used for active immunization against diphtheria and tetanus, often administered as a booster dose to children between 6 and 8 years of age. In the context of clinical research, such as trials conducted by GSK for the introduction of Boostrix (dTpa) in China, the 'Chinese DT vaccine' serves as the active control or comparator to evaluate the safety and immunogenicity of international vaccines against the established local standard of care. It is produced by domestic Chinese entities, most notably the institutes under the China National Biotec Group (CNBG).

Other names
Chinese DT vaccineAdsorbed Diphtheria and Tetanus Combined VaccineDT vaccine
02

Targets

BCR (Immunoglobulin G B Cell Receptor)Anti-tetanus toxin antibodyMHC II (Major histocompatibility complex class II receptor)

Beyond the preview

Go deeper on diphtheria and tetanus toxoids vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on diphtheria and tetanus toxoids vaccine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call